<ol class="cite-this-references"><li id="reference-A1262">Dohil R, Fidler M, Gangoiti JA, Kaskel F, Schneider JA, Barshop BA: Twice-daily cysteamine bitartrate therapy for children with cystinosis. J Pediatr. 2010 Jan;156(1):71-75.e1-3. doi: 10.1016/j.jpeds.2009.07.016. Epub . [<a href="/articles/A1262" target="_blank">Article</a>] </li><li id="reference-A218721">Elmonem MA, Veys KR, Soliman NA, van Dyck M, van den Heuvel LP, Levtchenko E: Cystinosis: a review. Orphanet J Rare Dis. 2016 Apr 22;11:47. doi: 10.1186/s13023-016-0426-y. [<a href="/articles/A218721" target="_blank">Article</a>] </li><li id="reference-A218726">Besouw M, Masereeuw R, van den Heuvel L, Levtchenko E: Cysteamine: an old drug with new potential. Drug Discov Today. 2013 Aug;18(15-16):785-92. doi: 10.1016/j.drudis.2013.02.003. Epub 2013 Feb 14. [<a href="/articles/A218726" target="_blank">Article</a>] </li><li id="reference-A218931">Cherqui S: Cysteamine therapy: a treatment for cystinosis, not a cure. Kidney Int. 2012 Jan;81(2):127-9. doi: 10.1038/ki.2011.301. [<a href="/articles/A218931" target="_blank">Article</a>] </li><li id="reference-A218936">Gangoiti JA, Fidler M, Cabrera BL, Schneider JA, Barshop BA, Dohil R: Pharmacokinetics of enteric-coated cysteamine bitartrate in healthy adults: a pilot study. Br J Clin Pharmacol. 2010 Sep;70(3):376-82. doi: 10.1111/j.1365-2125.2010.03721.x. [<a href="/articles/A218936" target="_blank">Article</a>] </li><li id="reference-A218941">Devereux G, Steele S, Griffiths K, Devlin E, Fraser-Pitt D, Cotton S, Norrie J, Chrystyn H, O'Neil D: An Open-Label Investigation of the Pharmacokinetics and Tolerability of Oral Cysteamine in Adults with Cystic Fibrosis. Clin Drug Investig. 2016 Aug;36(8):605-12. doi: 10.1007/s40261-016-0405-z. [<a href="/articles/A218941" target="_blank">Article</a>] </li><li id="reference-A218951">Langman CB, Greenbaum LA, Sarwal M, Grimm P, Niaudet P, Deschenes G, Cornelissen E, Morin D, Cochat P, Matossian D, Gaillard S, Bagger MJ, Rioux P: A randomized controlled crossover trial with delayed-release cysteamine bitartrate in nephropathic cystinosis: effectiveness on white blood cell cystine levels and comparison of safety. Clin J Am Soc Nephrol. 2012 Jul;7(7):1112-20. doi: 10.2215/CJN.12321211. Epub 2012 May 3. [<a href="/articles/A218951" target="_blank">Article</a>] </li><li id="reference-A218946">Dohil R, Cabrera BL, Gangoiti JA, Barshop BA, Rioux P: Pharmacokinetics of cysteamine bitartrate following intraduodenal delivery. Fundam Clin Pharmacol. 2014 Apr;28(2):136-43. doi: 10.1111/fcp.12009. Epub 2012 Oct 31. [<a href="/articles/A218946" target="_blank">Article</a>] </li><li id="reference-L15601">PRN News Wire: U.S. FDA Approves CYSTADROPS® (Cysteamine Ophthalmic Solution) 0.37%, A New Practical Treatment Option for the Ocular Manifestations of Cystinosis [<a href="https://www.prnewswire.com/news-releases/us-fda-approves-cystadrops-cysteamine-ophthalmic-solution-0-37-a-new-practical-treatment-option-for-the-ocular-manifestations-of-cystinosis-301118026.html" target="_blank">Link</a>] </li><li id="reference-L15606">FDA Approved Products: Cystadrops (cysteamine solution 0.37%) for ophthalmic use [<a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211302s000lbl.pdf" target="_blank">Link</a>] </li><li id="reference-L15611">FDA approved products: CYSTARAN (cysteamine 0.44%) for ophthalmic use [<a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/200740s000lbl.pdf" target="_blank">Link</a>] </li><li id="reference-L15616">FDA approved products: PROCYSBI (cysteamine bitartrate) delayed-release oral capsules [<a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203389s000lbl.pdf" target="_blank">Link</a>] </li><li id="reference-L15646">FDA Approved Products: CYSTAGON® (cysteamine bitartrate) oral capsules [<a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/020392s010lbl.pdf" target="_blank">Link</a>] </li></ol>